Skip to main content
SENORES PHARMACEUTICALS LIMITED logo

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2025-10-29 Call Transcript
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an intimation letter to stock exchanges about an upcoming earnings conference call for the quarter Q2FY26. It mentions the date and time of the call, the company representatives who will participate, and instructions for joining the call. It explicitly states that the audio recording and transcript will be published later, indicating this document is a notification about the call, not the transcript itself. The document length is short (2958 characters), and it does not contain any financial results or detailed discussion, only the announcement of the call. Therefore, this document is best classified as a Call Transcript (CT) announcement, but since it is only an intimation for the call and not the transcript itself, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement. However, given the specific nature of the announcement about the earnings call, the most appropriate classification is Call Transcript (CT) as it relates directly to the earnings call event. Confidence is high due to clear references to the earnings call and no financial data present.
2025-10-29 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing about a scheduled Board Meeting pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The letter states that the Board Meeting will consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. It also references the closure of the trading window as per insider trading regulations. The document does not contain any financial data or results itself but is an announcement of an upcoming board meeting where financial results will be approved. The document length is short (2405 characters) and it is clearly an intimation or announcement rather than the report itself. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement and notification to exchanges about the board meeting and financial results approval schedule, rather than the financial report or earnings release itself.
2025-10-29 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Audit Report / Information Classification · 100% confidence The document is titled 'Reconciliation of Share Capital Audit Report' for the quarter ended September 30, 2025, submitted under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It is signed by a practicing Company Secretary and includes detailed information about the company's share capital structure, dematerialized shares, and compliance with regulatory requirements. The document is an audit report specifically reconciling share capital, not a full annual or quarterly financial report. It is not a brief announcement or a certification letter but a standalone audit report as per regulatory norms. Therefore, it fits the category of Audit Report / Information (AR). Q2 2025
2025-10-09 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges (BSE and NSE) regarding a change in the email address of the company's Registrar and Share Transfer Agent (RTA). It does not contain any financial data, report, or detailed disclosures about company performance, management changes, or shareholder votes. It is an informational update about contact details, which is a regulatory announcement but does not fit into categories like Annual Report, Interim Report, or Management Information. Given the short length (2127 characters) and the nature of the content, this is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-10-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2025. It is issued by the Registrar and Share Transfer Agent confirming dematerialisation of securities and related compliance. The document is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or management discussion but is a formal attestation related to securities and share transfer regulations. The document length is 3543 characters, which is relatively short and focused on certification. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a financial report or announcement of a report.
2025-10-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window for insiders ahead of the announcement of unaudited financial results for the quarter and half year ending September 30, 2025. It references compliance with SEBI regulations on insider trading and informs about the trading restrictions period. The document does not contain any financial data, results, or detailed report content. It is a regulatory announcement related to trading restrictions and upcoming financial results, not the financial results or report itself. The document length is short (2142 characters), and it serves as an official notification to the exchanges rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2025-09-26 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.